Seeking Future Cures

Fighting deadly infectious diseases

Next-generation triterpenoid antifungals

When working in the field of life-threatening infectious diseases, you are racing against rapidly evolving pathogens.

Of the dozens of potential assets within the fungerp family of triterpenoid antifungals, we have narrowed the focus to the most promising of the antifungal compounds to investigate powerful systemic therapeutic options. The development of the second-generation treatments has begun.

SCY-247: Advanced chemistry and favorable tolerability with enormous potential in the fight against deadly fungi

Some of the key advantages of triterpenoid are the broad spectrum of activity, safety and high tissue penetration compared to other antifungals. SCY-247 is a second generation triterpenoid showing significant promise. The collective attributes of broad spectrum of activity, favorable tolerability and high tissue penetration make SCY-247 an attractive development candidate for the treatment and prevention of difficult to treat and emerging fungal infections like C. auris, and those in anatomic areas not adequately reached by other antifungals.

SCY-247 Key attributes

  • Broad-spectrum activity against yeasts, molds, pneumocystis and dimorphic fungi
  • Fungicidal against Candida spp. and potentially Aspergillus spp.
  • Extensive tissue penetration
  • Active against multi-drug resistant (MDR) pathogens, including potent activity against C. auris
  • Suitable for both IV and oral formulations
  • Potential for Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designations
  • Validated mechanism of action (MOA): Glucan synthase inhibition – click here to see how our MOA works

Our Pipeline

We are working on medicines that have the potential to save lives.

Learn More

Our Data

SCYNEXIS regularly presents key infectious disease study data at top medical meetings.

Learn More